Expert opinion on drug delivery最新文献_第10页

Metabolism and structure of PDA as the target for new therapies: possibilities and limitations for nanotechnology. 作为新疗法靶标的 PDA 的代谢和结构：纳米技术的可能性和局限性。

Expert opinion on drug delivery Pub Date : 2024-06-01 Epub Date: 2024-06-25 DOI: 10.1080/17425247.2024.2370492

Adrianna Zygmunt, Jerzy Gubernator

{"title":"Metabolism and structure of PDA as the target for new therapies: possibilities and limitations for nanotechnology.","authors":"Adrianna Zygmunt, Jerzy Gubernator","doi":"10.1080/17425247.2024.2370492","DOIUrl":"10.1080/17425247.2024.2370492","url":null,"abstract":"Introduction: Certainly, pancreatic ductal adenocarcinoma poses one of the greatest challenges in current oncology. The dense extracellular matrix and low vessel density in PDA tumor impede the effective delivery of drugs, primarily due to the short pharmacokinetics of most drugs and potential electrostatic interactions with stroma components.Area covered: Owing to the distinctive metabolism of PDA and challenges in accessing nutrients, there is a growing interest in cell metabolism inhibitors as a potential means to inhibit cancer development. However, even if suitable combinations of inhibitors are identified, the question about their administration remains, as the same hindrances that impede effective treatment with conventional drugs will also hinder the delivery of inhibitors. Methods including nanotechnology to increase drugs in PDA penetrations are reviewed and discussed.Expert opinion: Pancreatic cancer is one of the most difficult tumors to treat due to the small number of blood vessels, high content of extracellular matrix, and specialized resistance mechanisms of tumor cells. One possible method of treating this tumor is the use of metabolic inhibitors in combinations that show synergy. Despite promising results in in vitro tests, their effect is uncertain due to the tumor's structure. In the case of pancreatic cancer, priming of the tumor tissue is required through the sequential administration of drugs that generate blood vessels, increase blood flow, and enhance vascular permeability and extracellular matrix. The use of drug carriers with a size of 10-30 nm may be crucial in the therapy of this cancer.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"845-865"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141428536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Building respirable powder architectures: utilizing polysaccharides for precise control of particle morphology for enhanced pulmonary drug delivery. 构建可吸入粉末结构：利用多糖精确控制颗粒形态，增强肺部给药效果。

Expert opinion on drug delivery Pub Date : 2024-06-01 Epub Date: 2024-07-08 DOI: 10.1080/17425247.2024.2376702

Kazunori Kadota, Hiromasa Uchiyama, Tero Kämäräinen, Shunsuke Tanaka, Yuichi Tozuka

{"title":"Building respirable powder architectures: utilizing polysaccharides for precise control of particle morphology for enhanced pulmonary drug delivery.","authors":"Kazunori Kadota, Hiromasa Uchiyama, Tero Kämäräinen, Shunsuke Tanaka, Yuichi Tozuka","doi":"10.1080/17425247.2024.2376702","DOIUrl":"10.1080/17425247.2024.2376702","url":null,"abstract":"Introduction: Dry powder inhaler (DPI) formulations are gaining attention as universal formulations with applications in a diverse range of drug formulations. The practical application of DPIs to pulmonary drugs requires enhancing their delivery efficiency to the target sites for various treatment modalities. Previous reviews have not explored the relation between particle morphology and delivery to different pulmonary regions. This review introduces new approaches to improve targeted DPI delivery using novel particle design such as supraparticles and metal-organic frameworks based on cyclodextrin.Areas covered: This review focuses on the design of DPI formulations using polysaccharides, promising excipients not yet approved by regulatory agencies. These excipients can be used to design various particle morphologies by controlling their physicochemical properties and manufacturing methods.Expert opinion: Challenges associated with DPI formulations include poor access to the lungs and low delivery efficiency to target sites in the lung. The restricted applicability of typical excipients contributes to their limited use. However, new formulations based on polysaccharides are expected to establish a technological foundation for the development of DPIs capable of delivering modalities specific to different lung target sites, thereby enhancing drug delivery.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"945-963"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liposome-based hybrid drug delivery systems with DNA nanostructures and metallic nanoparticles. 基于脂质体的 DNA 纳米结构与金属纳米颗粒混合给药系统。

Expert opinion on drug delivery Pub Date : 2024-06-01 Epub Date: 2024-07-04 DOI: 10.1080/17425247.2024.2375389

Olavi Reinsalu, Mart Ernits, Veikko Linko

{"title":"Liposome-based hybrid drug delivery systems with DNA nanostructures and metallic nanoparticles.","authors":"Olavi Reinsalu, Mart Ernits, Veikko Linko","doi":"10.1080/17425247.2024.2375389","DOIUrl":"10.1080/17425247.2024.2375389","url":null,"abstract":"Introduction: This review discusses novel hybrid assemblies that are based on liposomal formulations. The focus is on the hybrid constructs that are formed through the integration of liposomes/vesicles with other nano-objects such as nucleic acid nanostructures and metallic nanoparticles. The aim is to introduce some of the recent, specific examples that bridge different technologies and thus may form a new platform for advanced drug delivery applications.Areas covered: We present selected examples of liposomal formulations combined with complex nanostructures either based on biomolecules like DNA origami or on metallic materials - metal/metal oxide/magnetic particles and metallic nanostructures, such as metal organic frameworks - together with their applications in drug delivery and beyond.Expert opinion: Merging the above-mentioned techniques could lead to development of drug delivery vehicles with the most desirable properties; multifunctionality, biocompatibility, high drug loading efficiency/accuracy/capacity, and stimuli-responsiveness. In the near future, we believe that especially the strategies combining dynamic, triggerable and programmable DNA nanostructures and liposomes could be used to create artificial liposome clusters for multiple applications such as examining protein-mediated interactions between lipid bilayers and channeling materials between liposomes for enhanced pharmacokinetic properties in drug delivery.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"905-920"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Injectable long-acting formulations (ILAFs) and manufacturing techniques. 注射用长效制剂 (ILAF) 和制造技术。

Expert opinion on drug delivery Pub Date : 2024-06-01 Epub Date: 2024-07-17 DOI: 10.1080/17425247.2024.2374807

Kosheli Thapa Magar, Hamza Boucetta, Zongmin Zhao, Ying Xu, Zhengxia Liu, Wei He

{"title":"Injectable long-acting formulations (ILAFs) and manufacturing techniques.","authors":"Kosheli Thapa Magar, Hamza Boucetta, Zongmin Zhao, Ying Xu, Zhengxia Liu, Wei He","doi":"10.1080/17425247.2024.2374807","DOIUrl":"10.1080/17425247.2024.2374807","url":null,"abstract":"Introduction: Most therapeutics delivered using short-acting formulations need repeated administration, which can harm patient compliance and raise failure risks related to inconsistent treatment. Injectable long-acting formulations (ILAFs) are controlled/sustained-release formulations fabricated to deliver active pharmaceutical ingredients (APIs) and extend their half-life over days to months. Longer half-lives of ILAFs minimize the necessity for frequent doses, increase patient compliance, and reduce the risk of side effects from intravenous (IV) infusions. Using ILAF technologies, the immediate drug release can also be controlled, thereby minimizing potential adverse effects due to high initial drug blood concentrations.Area covered: In this review, we have discussed various ILAFs, their physiochemical properties, fabrication technologies, advantages, and practical issues, as well as address some major challenges in their application. Especially, the approved ILAFs are highlighted.Expert opinion: ILAFs are sustained-release formulations with extended activity, which can improve patient compliance. ILAFs are designed to deliver APIs like proteins and peptides and extend their half-life over days to months. The specific properties of each ILAF preparation, such as extended-release and improved drug targeting capabilities, make them an effective approach for precise and focused therapy. Furthermore, this is especially helpful for biopharmaceuticals with short biological half-lives and low stability since most environmental conditions can protect them from sustained-release delivery methods.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"881-904"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harness arsenic in medicine: current status of arsenicals and recent advances in drug delivery. 在医学中利用砷：砷化物的现状和给药方面的最新进展。

Expert opinion on drug delivery Pub Date : 2024-06-01 Epub Date: 2024-06-28 DOI: 10.1080/17425247.2024.2372363

Fan Liu, Yibin Deng, Anru Wang, Tao Yang, Hengte Ke, Yongan Tang, Hong Wu, Huabing Chen

{"title":"Harness arsenic in medicine: current status of arsenicals and recent advances in drug delivery.","authors":"Fan Liu, Yibin Deng, Anru Wang, Tao Yang, Hengte Ke, Yongan Tang, Hong Wu, Huabing Chen","doi":"10.1080/17425247.2024.2372363","DOIUrl":"10.1080/17425247.2024.2372363","url":null,"abstract":"Introduction: Arsenicals have a special place in the history of human health, acting both as poison and medicine. Having been used to treat a variety of diseases in the past, the success of arsenic trioxide (ATO) in treating acute promyelocytic leukemia (APL) in the last century marked its use as a drug in modern medicine. To expand their role against cancer, there have been clinical uses of arsenicals worldwide and progress in the development of drug delivery for various malignancies, especially solid tumors.Areas covered: In this review, conducted on Google Scholar [1977-2024], we start with various forms of arsenicals, highlighting the well-known ATO. The mechanism of action of arsenicals in cancer therapy is then overviewed. A summary of the research progress in developing new delivery approaches (e.g. polymers, inorganic frameworks, and biomacromolecules) in recent years is provided, addressing the challenges and opportunities in treating various malignant tumors.Expert opinion: Reducing toxicity and enhancing therapeutic efficacy are guidelines for designing and developing new arsenicals and drug delivery systems. They have shown potential in the fight against cancer and emerging pathogens. New technologies and strategies can help us harness the potency of arsenicals and make better products.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"867-880"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulation of ferroptosis by nanotechnology for enhanced cancer immunotherapy. 利用纳米技术调控铁突变，增强癌症免疫疗法。

Expert opinion on drug delivery Pub Date : 2024-06-01 Epub Date: 2024-07-16 DOI: 10.1080/17425247.2024.2379937

Haohan Zhou, Yiyun Cheng, Quan Huang, Jianru Xiao

{"title":"Regulation of ferroptosis by nanotechnology for enhanced cancer immunotherapy.","authors":"Haohan Zhou, Yiyun Cheng, Quan Huang, Jianru Xiao","doi":"10.1080/17425247.2024.2379937","DOIUrl":"10.1080/17425247.2024.2379937","url":null,"abstract":"Introduction: This review explores the innovative intersection of ferroptosis, a form of iron-dependent cell death, with cancer immunotherapy. Traditional cancer treatments face limitations in efficacy and specificity. Ferroptosis as a new paradigm in cancer biology, targets metabolic peculiarities of cancer cells and may potentially overcome such limitations, enhancing immunotherapy.Area covered: This review centers on the regulation of ferroptosis by nanotechnology to augment immunotherapy. It explores how nanoparticle-modulated ferroptotic cancer cells impact the TME and immune responses. The dual role of nanoparticles in modulating immune response through ferroptosis are also discussed. Additionally, it investigates how nanoparticles can be integrated with various immunotherapeutic strategies, to optimize ferroptosis induction and cancer treatment efficacy. The literature search was conducted using PubMed and Google Scholar, covering articles published up to March 2024.Expert opinion: The manuscript underscores the promising yet intricate landscape of ferroptosis in immunotherapy. It emphasizes the need for a nuanced understanding of ferroptosis' impact on immune cells and the TME to develop more effective cancer treatments, highlighting the potential of nanoparticles in enhancing the efficacy of ferroptosis and immunotherapy. It calls for deeper exploration into the molecular mechanisms and clinical potential of ferroptosis to fully harness its therapeutic benefits in immunotherapy.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"921-943"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and opportunities in neurometabolic disease treatment with enzyme delivery. 用酶制剂治疗神经代谢疾病的挑战与机遇。

Expert opinion on drug delivery Pub Date : 2024-06-01 Epub Date: 2024-07-04 DOI: 10.1080/17425247.2024.2375388

David Begley, Reinhard Gabathuler, Gregory Pastores, Angeles Garcia-Cazorla, Diego Ardigò, Maurizio Scarpa, Rosella Tomanin, Giovanni Tosi

{"title":"Challenges and opportunities in neurometabolic disease treatment with enzyme delivery.","authors":"David Begley, Reinhard Gabathuler, Gregory Pastores, Angeles Garcia-Cazorla, Diego Ardigò, Maurizio Scarpa, Rosella Tomanin, Giovanni Tosi","doi":"10.1080/17425247.2024.2375388","DOIUrl":"10.1080/17425247.2024.2375388","url":null,"abstract":"Introduction: Neurometabolic disorders remain challenging to treat, largely due to the limited availability of drugs that can cross the blood-brain barrier (BBB) and effectively target brain impairment. Key reasons for inadequate treatment include a lack of coordinated knowledge, few studies on BBB status in these diseases, and poorly designed therapies.Areas covered: This paper provides an overview of current research on neurometabolic disorders and therapeutic options, focusing on the treatment of neurological involvement. It highlights the limitations of existing therapies, describes innovative protocols recently developed, and explores new opportunities for therapy design and testing, some of which are already under investigation. The goal is to guide researchers toward innovative and potentially more effective treatments.Expert opinion: Advancing research on neurometabolic diseases is crucial for designing effective treatment strategies. The field suffers from a lack of collaboration, and a strong collective effort is needed to enhance synergy, increase knowledge, and develop a new therapeutic paradigm for neurometabolic disorders.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"817-828"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the efficacy of inhaled curcumin: a new mode of administration for an old molecule. 吸入姜黄素疗效综述：老分子的新给药模式。

Expert opinion on drug delivery Pub Date : 2024-05-21 DOI: 10.1080/17425247.2024.2358880

Nima Rastegar-Pouyani, Tenzin Sonam Dongsar, Mahshid Ataei, Shokoufeh Hassani, Eric Gumpricht, Prashant Kesharwani, Amirhossein Sahebkar

{"title":"An overview of the efficacy of inhaled curcumin: a new mode of administration for an old molecule.","authors":"Nima Rastegar-Pouyani, Tenzin Sonam Dongsar, Mahshid Ataei, Shokoufeh Hassani, Eric Gumpricht, Prashant Kesharwani, Amirhossein Sahebkar","doi":"10.1080/17425247.2024.2358880","DOIUrl":"10.1080/17425247.2024.2358880","url":null,"abstract":"Introduction: Curcumin is a polyphenol with a variety of pharmacological actions. Despite its therapeutic effects and well-known safety profile, the utility of curcumin has been limited due to its deprived physical, chemical, and pharmacokinetic profile resulting from limited solubility, durability, prompt deterioration and pitiable systemic availability. Employment of an amalgamated framework integrating the potential advantages of a nanoscaffold alongside the beneficial traits of inhalational drug delivery system beautifully bringing down the restricting attributes of intended curative interventions and further assures its clinical success.Areas covered: Current review discussed different application of inhalable nanocurcumin in different medical conditions. Lung diseases have been the prime field in which inhalable nanocurcumin had resulted in significant beneficial effects. Apart from this several lung protective potentials of the inhaled nanocurcumin have been discussed against severe pulmonary disorders such as pulmonary fibrosis, radiation pneumonitis and IUGR induced bronchopulmonary dysplasia. Also, application of the disclosed intervention in the clinical management of COVID-19 and Alzheimer's Disease has been discussed.Expert opinion: In this portion, the potential of inhalable nanocurcumin in addressing various medical conditions along with ongoing advancements in nanoencapsulation techniques and the existing challenges in transitioning from pre-clinical models to clinical practice has been summarized.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-ANDA strategy and human factors activities to de-risk pharmaceutical companies ANDA submission of drug-device combination products: case study of a formative comparative use human factors study. 为降低制药公司提交药物-器械组合产品 ANDA 的风险而开展的 ANDA 前战略和人为因素活动：形成性比较使用人为因素研究的案例研究。

Expert opinion on drug delivery Pub Date : 2024-05-16 DOI: 10.1080/17425247.2024.2356678

Laurie Brunet-Manquat, Anne Combedazou, Bomby Ahuja, Alice Maden, Claire Ramus, Tatsiana Mardovina, Cécile Frolet

{"title":"Pre-ANDA strategy and human factors activities to de-risk pharmaceutical companies ANDA submission of drug-device combination products: case study of a formative comparative use human factors study.","authors":"Laurie Brunet-Manquat, Anne Combedazou, Bomby Ahuja, Alice Maden, Claire Ramus, Tatsiana Mardovina, Cécile Frolet","doi":"10.1080/17425247.2024.2356678","DOIUrl":"https://doi.org/10.1080/17425247.2024.2356678","url":null,"abstract":"BACKGROUND\u0000This article presents a strategy that a Drug Delivery Device Developer (DDDD) has adopted to support Abbreviated New Drug Application (ANDA) submissions of drug-device combination products. As per the related FDA guidance, a threshold analysis should be compiled. If 'other differences' between the Reference Listed Drug (RLD) and the generic drug devices are identified, a Comparative Use Human Factors (CUHF) study may be requested.\u0000\u0000\u0000METHODS\u0000The DDDD performed task analysis and physical comparison to assess the pen injector design differences. Then, a formative CUHF study with 25 participants simulating injections using both RLD and the generic pen injectors was conducted.\u0000\u0000\u0000RESULTS\u0000After each participant completed four simulated injections, similar type and rates of use error between the RLD (0.70) and generic (0.68) pen injectors were observed.\u0000\u0000\u0000CONCLUSION\u0000DDDDs can support pharmaceutical companies in the ANDA submission strategy of their drug-device combination product by initiating comparative task analysis and physical comparison of the device as inputs for the threshold analysis. If 'other differences' are identified, a formative CUHF study can be performed. As shown in our case study, this approach can be leveraged to support the sample size calculation and non-inferiority margin determination for a CUHF study with the final combination product.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":"58 38","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140970352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Graphene-based materials as nanoplatforms for antiviral therapy and prophylaxis. 石墨烯基材料作为抗病毒治疗和预防的纳米平台。

Expert opinion on drug delivery Pub Date : 2024-05-01 Epub Date: 2024-06-10 DOI: 10.1080/17425247.2024.2364652

Daniela Iannazzo, Salvatore V Giofrè, Claudia Espro, Consuelo Celesti

{"title":"Graphene-based materials as nanoplatforms for antiviral therapy and prophylaxis.","authors":"Daniela Iannazzo, Salvatore V Giofrè, Claudia Espro, Consuelo Celesti","doi":"10.1080/17425247.2024.2364652","DOIUrl":"10.1080/17425247.2024.2364652","url":null,"abstract":"Introduction: The dramatic effects caused by viral diseases have prompted the search for effective therapeutic and preventive agents. In this context, 2D graphene-based nanomaterials (GBNs) have shown great potential for antiviral therapy, enabling the functionalization and/or decoration with biomolecules, metals and polymers, able to improve their interaction with viral nanoparticles.Areas covered: This review summarizes the most recent advances of the antiviral research related to 2D GBNs, based on their antiviral mechanism of action. Their ability to inactivate viruses by inhibiting the entry inside cells, or through drug/gene delivery, or by stimulating the host immune response are here discussed. As reported, biological studies performed in vitro and/or in vivo allowed to demonstrate the antiviral activity of the developed GBNs, at different stages of the virus life cycle and the evaluation of their long-term toxicity. Other mechanisms closely related to the physicochemical properties of GBNs are also reported, demonstrating the potential of these materials for antiviral prophylaxis.Expert opinion: GBNs represent valuable tools to fight emerging or reemerging viral infections. However, their translation into the clinic requires standardized scale-up procedures leading to the reliable and reproducible synthesis of these nanomaterials with suitable physicochemical properties, as well as more in-depth pharmacological and toxicological investigations. We believe that multidisciplinary approaches will give valuable solutions to overcome the encountered limitations in the application of GBNs in biomedical and clinical field.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"751-766"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141263574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0